14 
” 5 . Materiad voild be added to Part III, as follows: 
■No experijTents should be performed which involve: 
"(a) Deliberate transfer of a drug resistance trait to micro- 
organisre that are not known to acquire it naturally, if 
such acquisition oould canpronise the use of a drug to 
control disease agents in human or veterinary medicine or 
agriculture. 
"(b) Deliberate fonnation of reconbinant DMAs containing genes for 
the biosynthesis of toxins lethal for vertebrates at an ID50 
of less them 100 nanograms per kilogram body weight (e.g., the 
botulinun toxins, tetanus toxin, diphtheria toxin. Shigella 
dysenteriae neurotoxin). Guidelines for the cloning of DMAs 
containing genes coding for the biosynthesis of toxins which 
are lethal to vertebrates at 100 nanograms to 100 micrograms 
per kilogram body weight are specified in Appendix G. 
"6. Part IV of the Guidelines would be eliminated with the following excep- 
tions: 
"(a) Those definitions listed in Part IV-C which may be needed to 
clarify statements made elsewhere in the Guidelines shall be 
retained. 
■(b) Those portions of Part IV-E defining the composition of RAC 
and prescribing rules for RAC procedures shall be retained. 
■(c) The following statement shall be added: 
"Each institution conducting or sponsoring recombinant CNA 
research should take responsibility for monitoring its own 
activities in this area. Any unusual events that might be 
associated with the use of recombinant CNA molecules should 
be reported to the Director, NIH. 
■7. Section VI of the Guidelines will be eliminated, except for those 
portions of Section VI-F relevant to the protection of proprietary 
infonration." 
The vote on this substitute motion was Ccilled, and the vote was sixteen in 
favor, three opposed, and one abstention. 
Dr. Zinder requested that a motion be introduced in support of the Melberg- 
Zinder proposal to eliminate the Guidelines and the RAC. No motion was 
introduced . 
[ 205 ] 
